Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Form 144 filed for Ionis Pharmaceuticals (IONS) reports a proposed sale of common stock. The broker listed is Stifel Nicolaus & Company. The notice covers 203,814 shares with an aggregate market value of $12,230,307, to be sold approximately on 09/03/2025 on Nasdaq. The filer shows prior option-exercise acquisitions: 101,489 shares on 01/03/2022, 42,030 shares on 01/03/2023 and 102,900 shares on 01/01/2019, with payment in cash. Two small open-market sales by Brett Monia in July 2025 are also disclosed.
Ionis Pharmaceuticals (IONS) filed a Form 144 notifying a proposed sale of 3,162 shares of common stock to be executed through Stifel Nicolaus & Company on 09/03/2025. The filing reports an aggregate market value of $192,958.00 based on total shares outstanding of 159,391,229. The shares were acquired by option exercise: 928 shares on 01/03/2022 and 2,234 shares on 01/03/2023, with cash payment noted on the planned sale date. The filing includes the standard seller representation that no material nonpublic information is known to the selling person and indicates no securities sold in the past three months.
Ionis Pharmaceuticals (IONS) Form 144 notice reports a proposed sale of 19,658 shares of common stock to be executed through Stifel Nicolaus on 09/03/2025 with an aggregate market value of $1,195,421.00. The shares represent part of an award acquired on 01/02/2019 by option exercise; the planned proceeds will be received in cash.
The filing lists total outstanding shares of 159,391,229 for the issuer and discloses recent sales by the same person on 08/04/2025 of 7,095 and 2,454 shares generating gross proceeds of $303,074.00 and $105,627.00 respectively. The filer affirms no undisclosed material adverse information and provides a broker name and address for execution.
Notice of proposed sale under Rule 144: The filing reports the proposed sale of 28,000 common shares, acquired the same day by exercise of stock options and paid in cash. The broker named is UBS Financial Services, Inc. (11 Madison Avenue, New York). The aggregate market value of the shares is listed as $1,680,000.00, with 159,391,229 shares outstanding and an approximate sale date of 09/03/2024 on NASDAQ. The filer reports no securities sold in the past three months and includes the standard signature representation re: material nonpublic information and Rule 10b5-1 plan language.
Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS) reports a proposed sale of 33,600 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $1,931,664. The filing lists approximately 159,391,229 shares outstanding and indicates an approximate sale date of 09/02/2025 on NASD. The securities being sold were primarily acquired as compensation (restricted stock units) and via option exercises on various dates between 2015 and 2020, with individual lots and quantities detailed in the filing. No securities sold in the past three months are reported.
Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS) reports a proposed sale of 11,130 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $552,865.00. The filing lists 159,391,229 shares outstanding and an approximate sale date of 09/02/2025 on Nasdaq. The securities were acquired as Restricted Stock Units on 01/15/2021 (listed amount acquired: 23,976) and a payment date of 01/15/2017 with Cash noted under payment. No securities were reported sold in the past three months, and the filer attests they are unaware of undisclosed material adverse information.
Ionis Pharmaceuticals insider sale notice: This Form 144 shows a proposed sale of 10,000 shares of Ionis common stock through Stifel Nicolaus & Company, with an aggregate market value of $503,671. The filing reports the shares were acquired as restricted stock units on 01/15/2019 (16,802 units originally) and payment was in cash. The filer previously sold 10,000 shares on 08/05/2025 for $428,593. The company has 159,391,229 shares outstanding, so the proposed sale represents approximately 0.0063% of outstanding shares. The filer attests there is no undisclosed material information.
Ionis Pharmaceuticals, Inc. notified the market of a proposed sale of 13,050 shares of its common stock through Stifel Nicolaus & Company Inc., with an approximate aggregate market value of $711,418.00. The filing states the shares represent part of outstanding common stock of 159,391,229 shares and lists an approximate sale date of 09/02/2025 on Nasdaq. The filer acquired these shares on 01/04/2021 by exercising options from the issuer and plans to receive cash as payment. The notice reports no securities sold in the past three months for the account and includes the required representation that the seller is not aware of any undisclosed material adverse information.
Form 144 notice for Ionis Pharmaceuticals (IONS) reports a proposed sale of 20,000 shares of common stock through Stifel Nicolaus & Company on 09/02/2025 on Nasdaq with an aggregate market value of $1,018,296. The filing states there are 159,391,229 shares outstanding.
The securities to be sold were acquired as restricted stock units on 01/15/2017 totaling 78,321 shares, with payment noted as cash. The filing also discloses a prior sale by Lynne Parshall of 5,000 shares on 08/06/2025 for gross proceeds of $209,646. The notice includes the standard representation that the seller has no undisclosed material information.
Ionis Pharmaceuticals reported positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG). Across nearly 1,100 patients required to remain on standard-of-care lipid-lowering therapy, olezarsen produced highly statistically significant, placebo-adjusted mean reductions in fasting triglycerides of up to 72% and a highly statistically significant 85% reduction in acute pancreatitis events. Both 80 mg and 50 mg monthly doses met the primary endpoint at six months with strong p-values (p<0.0001), and the company described safety and tolerability as favorable.